SOURCE: Crucell N.V.

April 27, 2007 02:07 ET

Crucell Announces PER.C6® Licensing Agreement

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- April 27, 2007 --


Leiden, The Netherlands, April 27, 2007- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and Novartis Vaccines and Diagnostics, Inc. today announced the extension of a non-exclusive research license agreement for PER.C6®. The license agreement allows Novartis to use Crucell's PER.C6® cell technology in manufacturing alphavirus vectors for its vaccine research programs. Financial details were not disclosed.

About PER.C6® technology

The PER.C6® technology is a cell line developed for the development and large- scale manufacture of biopharmaceutical products including vaccines. Compared to conventional production technologies, the strengths of the PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. These characteristics, combined with its ability to support the growth of both human and animal viruses, make PER.C6® technology the biopharmaceutical production technology of choice for Crucell's current and potential pharmaceutical and biotechnology partners.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20- F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:

Crucell N.V.                   For Crucell in the US:
Leonard Kruimer                Redington, Inc.
Chief Financial Officer        Thomas Redington
Tel. +31-(0)71-524 8722        Tel. +1 212-926-1733
Leonard.Kruimer@crucell.com    tredington@redingtoninc.com

Barbara Mulder
Director Corporate Communications
Barbara.mulder@crucell.com
Tel. +31-(0)71-524 8722

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information